NovelStem International (OTCMKTS:NSTM), Inc. is a biotechnology company focused on advancing cell therapy manufacturing and regenerative medicine. Founded in 2006 and headquartered in Fort Lauderdale, Florida, the company specializes in the development and manufacture of closed‐system bioreactors, cryogenic storage solutions and microcarrier technologies for the isolation, expansion and preservation of stem cells and other therapeutic cell populations. Under the leadership of CEO Dr. Elaine Chen and CFO Mark Davis, NovelStem has built a reputation for providing cGMP‐compliant instruments and consumables that support integrated workflows for academic and commercial research organizations.
The company’s product portfolio includes single‐use bioreactor cartridges, automated cryopreservation vessels and microfluidic cell processing modules designed to streamline the production of cell‐based therapies. NovelStem’s proprietary closed‐loop systems enable scalable cell expansion, reducing the risk of contamination while improving yield and consistency. These technologies cater to the needs of pharmaceutical developers, contract development and manufacturing organizations (CDMOs) and hospital‐based cell therapy centers working on treatments for oncology, immune disorders and degenerative diseases.
NovelStem maintains a global footprint, with manufacturing and R&D facilities in the United States, Europe and Asia. The company’s regional offices in Shanghai and Munich support local clinical trials and collaborate with leading academic institutions to validate new applications for stem cell‐derived therapies. By aligning its engineering, quality and regulatory teams across multiple geographies, NovelStem ensures compliance with FDA, EMA and NMPA standards, facilitating product registrations and market entry worldwide.
Since its OTC listing in 2018, NovelStem has pursued strategic partnerships and acquisitions to expand its technological capabilities. In 2020, the company acquired BioCryo, a specialist in low‐temperature bio‐storage, and in 2022 it launched a joint development agreement with a major research hospital to advance next‐generation exosome isolation platforms. These initiatives underscore NovelStem’s commitment to innovation and position the company as a key supplier of end‐to-end solutions for the rapidly growing cell therapy sector.
